Solifenacin and Tolterodine are Equally Effective in the Treatment of Overactive Bladder Symptoms

Background/PurposeVarious antimuscarinic agents have been developed for the treatment of overactive bladder (OAB). More data comparing these agents are still required. This study evaluated the efficacy and safety of solifenacin and tolterodine in Taiwanese patients with OAB symptoms.MethodsThis was a prospective, randomized, open-label study. A total of 75 patients (25 men and 50 women) with OAB symptoms were randomized to treatment with solifenacin (n = 39) or tolterodine (n = 36). Efficacy and safety variables were assessed and compared with the baseline and between the two groups.ResultsAt week 12, solifenacin and tolterodine demonstrated equal efficacy in reducing the number of micturition (−2.56 ±3.31 vs. −2.44 ± 4.56, p = 0.58), urgency (−1.70 ± 3.07 vs. −1.15 ± 2.68, p =0.37) and incontinence (−2.79 ± 2.82 vs. −4.67 ± 9.29, p =0.28) episodes per 24 hours. There was no difference in improvement of the quality of life. The patient and physician assessments of treatment benefit were not statistically different for solifenacin and tolterodine (p = 0.23 and p = 0.52, respectively), with the majority showing benefits in both groups. The incidence of major adverse events, including dry mouth (18.0% vs. 8.3%, p = 0.31) and constipation (12.8% vs. 2.8%, p = 0.20) was not significantly different. Compared with baseline, the severity of dry mouth did not increase in either group.ConclusionBoth solifenacin and tolterodine are effective in treating key OAB symptoms, including urinary frequency, urgency and incontinence in the Taiwanese population. Both medications are comparably effective and safe, with the most common adverse effects being dry mouth and constipation.